Tonsil and Adenoid Removal Products Market Size

Tonsil & Adenoid Removal Products Market Analysis

The tonsil & adenoid removal products market is expected to register a CAGR of 7.3% over the forecast period.

The COVID-19 pandemic has had a substantial impact on the tonsil & adenoid removal products market initially. The imposition of lockdown and delay of non-urgent surgeries and non-COVID disease treatment decreased the number of tonsil and adenoid procedures in 2020. The high risk of COVID-19 led to prioritizing only critical surgeries and procedures, which restricted various otolaryngology services. For instance, in a study published in the Journal of Head and Neck in February 2022, the number of tonsil surgery decreased by up to 82% in Germany due to the pandemic. According to a study published in the Journal Laryngoscope Investigative Otolaryngology in July 2021, along with the delay and cancellation of elective surgeries during a pandemic. The COVID-19 lockdown decreased the incidence rates of tonsil infections, such as in children, which also led to a decrease in the volume of tympanostomies and tonsil surgeries in children. However, even during the pandemic, severe cases of tonsil surgeries were allowed and performed. For instance, in a study published in the European Annals of Otorhinolaryngology, Head and Neck Diseases in May 2020, tonsillectomy and adenoidectomy were performed without any delay in the case of severe obstructive sleep apnea syndrome in adults. Although, with the lifting of the lockdown and the resumption of the non-COVID, non-urgent, and elective procedures, the market is expected to regain its normal pace as it was in pre-COVID. For instance, in February 2022, the New South Wales Government announced the resumption of non-urgent elective surgeries and increased the overnight stay of the patients by 85% of pre-pandemic activity levels in the private hospitals. Further, in May 2022, the New York State Department of Health (DOH) announced the updated guideline for the resumption of nonurgent procedures and non-essential elective surgeries in hospitals, office-based surgery practices, diagnostic and treatment centers, and ambulatory surgery centers.

The market is expected to grow further at a stable pace with the lifting of the lockdown and the resumption of the non-COVID, non-urgent, and elective procedures globally.

Further, the increasing cases of tonsil and adenoid infections are also boosting the market's growth. According to a study published in the Lancet in June 2022, the pooled incidence rate of the group A Streptococcus throat infection calculated for children was 82.2 episodes per 100 child years for sore throat and 22.1 episodes per 100 child years for Strep A sore throat. A study published in Journal Nature in December 2022 has underlined the risk of the surging case of strep A after the death of over 13 children in the United Kingdom in the month of December 2022, which causes deadly scarlet fever. According to the STAT Pearls in 2021, the condition of adenoid hypertrophy has a prevalence rate of 34.5% in children.

Therefore, owing to the increasing prevalence of tonsil and adenoid infections, the studied market is anticipated to witness growth over the analysis period. However, the complication associated with the surgeries is likely to impede the market growth.